SI4114390T1 - Postopki zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA - Google Patents

Postopki zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA

Info

Publication number
SI4114390T1
SI4114390T1 SI202130266T SI202130266T SI4114390T1 SI 4114390 T1 SI4114390 T1 SI 4114390T1 SI 202130266 T SI202130266 T SI 202130266T SI 202130266 T SI202130266 T SI 202130266T SI 4114390 T1 SI4114390 T1 SI 4114390T1
Authority
SI
Slovenia
Prior art keywords
mutation
patients
methods
fabry disease
treating fabry
Prior art date
Application number
SI202130266T
Other languages
English (en)
Slovenian (sl)
Inventor
Elfrida Benjamin
Xiaoyang Wu
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75267607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI4114390(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of SI4114390T1 publication Critical patent/SI4114390T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SI202130266T 2020-03-06 2021-03-05 Postopki zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA SI4114390T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986297P 2020-03-06 2020-03-06
PCT/US2021/020984 WO2021178737A1 (en) 2020-03-06 2021-03-05 Methods of treating fabry disease in patients having a mutation in the gla gene
EP21715035.8A EP4114390B1 (en) 2020-03-06 2021-03-05 Methods of treating fabry disease in patients having a mutation in the gla gene

Publications (1)

Publication Number Publication Date
SI4114390T1 true SI4114390T1 (sl) 2025-03-31

Family

ID=75267607

Family Applications (1)

Application Number Title Priority Date Filing Date
SI202130266T SI4114390T1 (sl) 2020-03-06 2021-03-05 Postopki zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA

Country Status (25)

Country Link
US (1) US20230136297A1 (cg-RX-API-DMAC7.html)
EP (2) EP4527454A3 (cg-RX-API-DMAC7.html)
JP (2) JP7749572B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152547A (cg-RX-API-DMAC7.html)
CN (1) CN115427040A (cg-RX-API-DMAC7.html)
AR (1) AR122390A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021230371A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017881A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170718A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002423A1 (cg-RX-API-DMAC7.html)
DK (1) DK4114390T3 (cg-RX-API-DMAC7.html)
ES (1) ES3013813T3 (cg-RX-API-DMAC7.html)
FI (1) FI4114390T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250179T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070116T2 (cg-RX-API-DMAC7.html)
IL (1) IL296221A (cg-RX-API-DMAC7.html)
LT (1) LT4114390T (cg-RX-API-DMAC7.html)
MX (1) MX2022011030A (cg-RX-API-DMAC7.html)
PL (1) PL4114390T3 (cg-RX-API-DMAC7.html)
PT (1) PT4114390T (cg-RX-API-DMAC7.html)
RS (1) RS66530B1 (cg-RX-API-DMAC7.html)
SI (1) SI4114390T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500072T1 (cg-RX-API-DMAC7.html)
TW (1) TW202146020A (cg-RX-API-DMAC7.html)
WO (1) WO2021178737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3840753T (lt) * 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US11034946B2 (en) * 2017-10-05 2021-06-15 Research Foundation Of The City University Of New York Glycosylation independent proteins

Also Published As

Publication number Publication date
HUE070116T2 (hu) 2025-05-28
PL4114390T3 (pl) 2025-06-23
TW202146020A (zh) 2021-12-16
RS66530B1 (sr) 2025-03-31
ES3013813T3 (en) 2025-04-15
LT4114390T (lt) 2025-02-10
HRP20250179T1 (hr) 2025-04-11
EP4527454A2 (en) 2025-03-26
US20230136297A1 (en) 2023-05-04
AU2021230371A1 (en) 2022-09-29
JP2026016375A (ja) 2026-02-03
AR122390A1 (es) 2022-09-07
EP4114390B1 (en) 2024-12-04
SMT202500072T1 (it) 2025-03-12
EP4114390A1 (en) 2023-01-11
DK4114390T3 (da) 2025-02-24
CN115427040A (zh) 2022-12-02
JP7749572B2 (ja) 2025-10-06
KR20220152547A (ko) 2022-11-16
PT4114390T (pt) 2025-02-24
FI4114390T3 (fi) 2025-03-07
MX2022011030A (es) 2022-12-13
CL2022002423A1 (es) 2023-05-05
EP4527454A3 (en) 2025-09-24
WO2021178737A1 (en) 2021-09-10
BR112022017881A2 (pt) 2022-12-06
JP2023516753A (ja) 2023-04-20
IL296221A (en) 2022-11-01
CA3170718A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
IL290365A (en) Methods for treating Fabry disease in patients with a mutation in the gla gene
IL280961B2 (en) Methods for treating Fabry disease in patients with a mutation in the GLA gene
MX2023004922A (es) Inhibidores del factor de crecimiento endotelial vascular (vegf) para usarse en el tratamiento de degeneracion macular humeda.
PL4114390T3 (pl) Sposoby leczenia choroby fabry’ego u pacjentów z mutacją w genie gla
IL284554A (en) Structures for gene therapy to treat Wilson's disease
ES3066136T3 (en) Methods of treating fabry disease
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
GB202004498D0 (en) Activity-dependent gene therapy for neurological disorders
IL278898A (en) An immunogenic product containing interleukin-4 and/or interleukin-13 for the treatment of disorders associated with defective expression or activity of interleukin-4 and/or interleukin-13
IL284302A (en) History of N-(4-(oxazol-5-yl)phenyl)chroman-3-carboxamide and related compounds as stimulators of retinal progenitor cell production for the treatment of neuroretinal diseases
IL290250A (en) Targeted gene therapy to treat neurological diseases
IL314294A (en) Gene therapy for Gaucher disease
GB202104611D0 (en) Gene therapy for retinal disease
HK40084393A (en) Gene therapy treatment
GB202315668D0 (en) Gene therapy
CA3309844A1 (en) Methods of using radiprodil in the treatment of disorders
EP4294930A4 (en) GENE THERAPY FOR RETINAL DISEASES